Answers are grounded in this paper and cite their sources.
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that primarily affects the enthesis and may culminate in bony ankylosis of the spine. Despite TNF inhibitor (TNFi) being foundational in managing active inflammation, 30-40% of patients with AS remain non-responsive. Through longitudinal and multi-omics profiling of peripheral blood mononuclear cells from TNFi-receiving patients with AS, here we reveal that elevated type I IFN signatures at baseline are associated with poor TNFi response, leading to a paradoxical enhancement of IFN signatures and Th17 responses following TNFi therapy. Among type I IFN-related genes, we identify and validate AIF-1 as a predictive biomarker reflecting the inherent IFN signature that differentiates responders from non-responders. AIF-1 also contributes to an inflammatory cycle by increasing IFNα receptor expression and Th17 responses. In summary, our findings advocate for a personalized approach to managing AS by considering individual variations in AIF-1 levels and IFN signatures. TNF inhibitor (TNFi) has been used to manage active inflammation in ankylosing spondylitis (AS), but not all patients respond. Here, through longitudinal and multi-omics profiling, the authors show that elevated type-I IFN signature and allograft inflammatory factor-1 expression at baseline inversely correlate with TNFi responsiveness in AS patients.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: